Across TCGA pan-cancer cohorts, EPRS1 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated EPRS1 data layer compared with 24 for mass-spec protein and 6 for mutation status.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher EPRS1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EPRS1 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.
CCRCC and PDAC are the cancer types where EPRS1 mass-spec protein most reproducibly stratifies survival.